Immunomedics, Takeda deal

Immunomedics said Takeda terminated a 2008 deal and returned to Immunomedics rights to subcutaneous veltuzumab, a humanized anti-CD20 antibody. The termination comes after Immunomedics started arbitration proceedings in September to settle its allegations that delays by Takeda's Nycomed unit in developing veltuzumab were a material breach of the deal. Immunomedics said it still plans to pursue arbitration for damages. ...